"Endothelial progenitor cells" as a therapeutic strategy in cardiovascular disease

Current Vascular Pharmacology

Volumn 10, Issue 1, 2012, Pages 107-124

  Kränkel, Nicolle ^a,b   Lüscher, Thomas F ^a,b   Landmesser, Ulf ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cardiovascular disease; Cell dysfunction; Cell therapy; Endothelial progenitor cells

Indexed keywords

ACETYLSALICYLIC ACID; FUCOIDIN; IBUPROFEN; PARECOXIB; RECOMBINANT ERYTHROPOIETIN;

BONE MARROW CELL; CARDIOVASCULAR DISEASE; CELL THERAPY; DRUG TARGETING; ENDOTHELIAL PROGENITOR CELL; HUMAN; MICROVASCULAR ENDOTHELIAL CELL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION;

ANIMALS; CARDIOVASCULAR DISEASES; CELL SURVIVAL; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84857132897     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112798829832     Document Type: Review

References (287)

1. Tyldum GA, Schjerve IE, Tjonna AE, et al. Endothelialdysfunction induced by post-prandial lipemia: complete protection afforded by high-intensity aerobic interval exercise. J Am Coll Cardiol 2009; 53: 200-6.
2. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997; 79: 350-4.
3. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
4. Martin JW, Mousa SS, Shaker O, Mousa SA. The multiple faces of nicotine and its implications in tissue and wound repair. Exp Dermatol 2009; 18: 497-505.
5. Granger DN, Rodrigues SF, Yildirim A, Senchenkova EY. Microvascular responses to cardiovascular risk factors. Microcirculation 2010; 17: 192-205.
6. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
7. Strauer BE, Brehm M, Zeus T, et al. Repair of infracted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-8.
8. Risau W. Differentiation of endothelium. FASEB J 1995; 9: 926-33.
9. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
10. Schatteman GC, Dunnwald M, Jiao C. Biology of bone marrow-derived endothelial cell precursors. Am J Physiol Heart Circ Physiol 2007; 292: H1-18.
11. Rehman J, Li J, Orschell CM, March KL. Peripheral blood endothelial progenitor cells are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164-9.
12. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008; 51: 660-8.
13. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109: 1801-9.
14. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97: 3422-7.
15. Schmeisser A, Garlichs CD, Zhang H, et al. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cordlike structures in Matrigel under angiogenic conditions. Cardiovasc Res 2001; 49: 671-80.
16. Lenk K, Adams V, Lurz P, et al. Therapeutical potential of bloodderived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur Heart J 2005; 26: 1903-9.
17. Erbs S, Linke A, Adams V, et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res 2005; 97: 756-62.
18. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007; 317: 666-70.
19. Giannotti G, Doerries C, Mocharla PS, et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension 2010; 55: 1389-97.
20. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 288-93.
21. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 1584-95.
22. Awad O, Dedkov EI, Jiao C, Bloomer S, Tomanek RJ, Schatteman GC. Differential healing activities of CD34+ and CD14+ endothelial cell progenitors. Arterioscler Thromb Vasc Biol 2006; 26: 758-64.
23. Anghelina M, Krishnan P, Moldovan L, Moldovan NI. Monocytes and macrophages form branched cell columns in matrigel: implications for a role in neovascularization. Stem Cells Dev 2004; 13: 665-76.
24. Campagnolo P, Cesselli D, Al Haj Zen A, et al. Human adult vena saphena contains perivascular progenitor cells endowed with clonogenic and proangiogenic potential. Circulation 2010; 121: 1735-45.
25. Hagensen MK, Shim J, Falk E, Bentzon JF. Flanking recipient vasculature, not circulating progenitor cells, contributes to endothelium and smooth muscle in murine allograft vasculopathy. Arterioscler Thromb Vasc Biol 2011; 31: 808-13.
26. Bentzon JF, Weile C, Sondergaard CS, Hindkjaer J, Kassem M, Falk E. Smooth muscle cells in atherosclerosis originate from the local vessel wall and not circulating progenitor cells in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2006; 26: 2696-702.
27. Campagnolo P, Wong MM, Xu Q. Progenitor cells in arteriosclerosis: good or bad guys? Antioxid Redox Signal 2010; 15: 1013-27.
28. Klein D, Hohn HP, Kleff V, Tilki D, Ergun S. Vascular wall-resident stem cells. Histol Histopathol 2010; 25: 681-9.
29. Hibbert B, Chen YX, O'Brien ER. c-kit-immunopositive vascular progenitor cells populate human coronary in-stent restenosis but not primary atherosclerotic lesions. Am J Physiol Heart Circ Physiol 2004; 287: H518-24.
30. Shaw JP, Basch R, Shamamian P. Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45. Blood Cells Mol Dis 2004; 32: 168-75.
31. Purhonen S, Palm J, Rossi D, et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 2008; 105: 6620-5.
32. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998; 101: 40-50.
33. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-47.
34. Dewald O, Zymek P, Winkelmann K, et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005; 96: 881-9.
35. Doyle B, Sorajja P, Hynes B, et al. Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1. Stem Cells Dev 2008; 17: 941-51.
36. Korf-Klingebiel M, Kempf T, Sauer T, et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur Heart J 2008; 29: 2851-8.
37. Roeske F, Stein A, Salameh A, et al. Activation of cardiomyocytes depending on their proximity to human bone marrow stem cells. Thorac Cardiovasc Surg 2011; 59: 78-84.
38. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004; 94: 1543-53.
39. Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 2009; 81: 457-64.
40. Sun J, Li SH, Liu SM, et al. Improvement in cardiac function after bone marrow cell thearpy is associated with an increase in myocardial inflammation. Am J Physiol Heart Circ Physiol 2009; 296: H43-50.
41. Al Haj Zen A, Oikawa A, Bazan-Peregrino M, Meloni M, Emanueli C, Madeddu P. Inhibition of delta-like-4-mediated signaling impairs reparative angiogenesis after ischemia. Circ Res 2010; 107: 283-93.
42. Arras M, Strasser R, Mohri M, et al. Tumor necrosis factor-alpha is expressed by monocytes/macrophages following cardiac microembolization and is antagonized by cyclosporine. Basic Res Cardiol 1998; 93: 97-107.
43. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-8.
44. Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998; 111: 1-6.
45. Izquierdo E, Canete JD, Celis R, et al. Immature blood vessels in rheumatoid synovium are selectively depleted in response to antiTNF therapy. PLoS One 2009; 4: e8131.
46. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-3.
47. Yu J, deMuinck ED, Zhuang Z, et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci USA 2005; 102: 10999-1004.
48. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-21.
49. Moore XL, Lu J, Sun L, Zhu CJ, Tan P, Wong MC. Endothelial progenitor cells' homing specificity to brain tumors. Gene Ther 2004; 11: 811-8.
50. Oh HK, Ha JM, O E, et al. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2. Cancer Res 2007; 67: 4851-9.
51. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009; 6: e1000029.
52. Ando T, Yujiri T, Mitani N, et al. Donor cell-derived acute myeloid leukemia after unrelated umbilical cord blood transplantation. Leukemia 2006; 20: 744-5.
53. Lin Q, Fu Q, Zhang Y, et al. Tumourigenesis in the infarcted rat heart is eliminated through differentiation and enrichment of the transplanted embryonic stem cells. Eur J Heart Fail 2010; 12: 1179-85.
54. Kiuru M, Boyer JL, O'Connor TP, Crystal RG. Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell 2009; 4: 289-300.
55. McCarthy MJ, Loftus IM, Thompson MM, et al. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999; 30: 261-8.
56. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003; 108: 2270-4.
57. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-25.
58. Doehring LC, Heeger C, Aherrahrou Z, et al. Myeloid CD34+CD13+ precursor cells transdifferentiate into chondrocytelike cells in atherosclerotic intimal calcification. Am J Pathol 2010; 177: 473-80.
59. Daub K, Langer H, Seizer P, et al. Platelets induce differentiation of human CD34+ progenitor cells into foam cells and endothelial cells. FASEB J 2006; 20: 2559-61.
60. Lemstrom KB, Krebs R, Nykanen AI, et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002; 105: 2524-30.
61. George J, Afek A, Abashidze A, et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25: 2636-41.
62. Hu Y, Zhang Z, Torsney E, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoEdeficient mice. J Clin Invest 2004; 113: 1258-65.
63. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-6.
64. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
65. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
66. Puska P. From Framingham to North Karelia: from descriptive epidemiology to public health action. Prog Cardiovasc Dis 2010; 53: 15-20.
67. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007; 28: 766-72.
68. Assmus B, Tonn T, Seeger FH, et al. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol 2010; 55: 1385-94.
69. Hansen-Smith FM, Morris LW, Greene AS, Lombard JH. Rapid microvessel rarefaction with elevated salt intake and reduced renal mass hypertension in rats. Circ Res 1996; 79: 324-30.
70. Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007; 10: 103-17.
71. Su RJ, Zhang XB, Li K, et al. Platelet-derived growth factor promotes ex vivo expansion of CD34+ cells from human cord blood and enhances long-term culture-initiating cells, non-obese diabetic/severe combined immunodeficient repopulating cells and formation of adherent cells. Br J Haematol 2002; 117: 735-46.
72. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002; 105: 732-8.
73. Sen S, Merchan J, Dean J, et al. Autologous transplantation of endothelial progenitor cells genetically modified by adenoassociated viral vector delivering insulin-like growth factor-1 gene after myocardial infarction. Hum Gene Ther 2010; 21: 1327-34.
74. Kaur S, Kumar TR, Uruno A, Sugawara A, Jayakumar K, Kartha CC. Genetic engineering with endothelial nitric oxide synthase improves functional properties of endothelial progenitor cells from patients with coronary artery disease: an in vitro study. Basic Res Cardiol 2009; 104: 739-49.
75. Marrotte EJ, Chen DD, Hakim JS, Chen AF. Manganese superoxide dismutase expression in endothelial progenitor cells accelerates wound healing in diabetic mice. J Clin Invest 2010; 120: 4207-19.
76. Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptorgamma agonist rosiglitazone. Circulation 2007; 116: 163-73.
77. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011; 12: 301-15.
78. Hedman M, Hartikainen J, Yla-Herttuala S. Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Ther 2011; 18: 743-9.
79. Sun Q, Silva EA, Wang A, et al. Sustained release of multiple growth factors from injectable polymeric system as a novel therapeutic approach towards angiogenesis. Pharm Res 2010; 27: 264-71.
80. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92: 1049-55.
81. Fadini GP, Albiero M, Boscaro E, et al. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biol Int 2010; 34: 709-15.
82. Spyridopoulos I, Haendeler J, Urbich C, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004; 110: 3136-42.
83. Emanueli C, Zacheo A, Minasi A, et al. Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler Thromb Vasc Biol 2000; 20: 2379-85.
84. Stone OA, Richer C, Emanueli C, et al. Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol 2009; 29: 657-64.
85. Chao J, Shen B, Gao L, Xia CF, Bledsoe G, Chao L. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem 2010; 391: 345-55.
86. Krankel N, Katare RG, Siragusa M, et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res 2008; 103: 1335-43.
87. Krankel N, Armstrong SP, McArdle CA, Dayan C, Madeddu P. Distinct kinin-induced functions are altered in circulating cells of young type 1 diabetic patients. PLoS One 2010; 5: e11146.
88. Spinetti G, Fortunato O, Cordella D, et al. Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells. Circ Res 2011; 108: 284-93.
89. Emanueli C, Caporali A, Krankel N, Cristofaro B, Van Linthout S, Madeddu P. Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia. Front Biosci 2007; 12: 2003-12.
90. Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent Results Cancer Res 2010; 180: 103-14.
91. Levanon K, Varda-Bloom N, Greenberger S, et al. Vascular wall maturation and prolonged angiogenic effect by endothelial-specific platelet-derived growth factor expression. Pathobiology 2006; 73: 149-58.
92. Kupatt C, Hinkel R, Pfosser A, et al. Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion role of vessel maturation. J Am Coll Cardiol 2010; 56: 414-22.
93. Walker PA, Shah SK, Jimenez F, et al. Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: preserving the blood brain barrier via an interaction with splenocytes. Exp Neurol 2010; 225: 341-52.
94. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: ra81.
95. Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39: 133-44.
96. Ogawa R, Tanaka C, Sato M, et al. Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. Biochem Biophys Res Commun 2010; 398: 723-9.
97. Aoki N, Yokoyama R, Asai N, et al. Adipocyte-derived microvesicles are associated with multiple angiogenic factors and induce angiogenesis in vivo and in vitro. Endocrinology 2010; 151: 2567-76.
98. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci USA 2009; 106: 3794-9.
99. Ferrari N, Glod J, Lee J, Kobiler D, Fine HA. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Ther 2003; 10: 647-56.
100. Di Santo S, Yang Z, Wyler von Ballmoos M, et al. Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One 2009; 4: e5643.
101. Feig JE, Rong JX, Shamir R, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci USA 2011; 108: 7166-71.
102. Liu ML, Reilly MP, Casasanto P, McKenzie SE, Williams KJ. Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles. Arterioscler Thromb Vasc Biol 2007; 27: 430-5.
103. Su YR, Blakemore JL, Zhang Y, Linton MF, Fazio S. Lentiviral transduction of apoAI into hematopoietic progenitor cells and macrophages: applications to cell therapy of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1439-46.
104. Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004; 109: 220-6.
105. Yoder MC. NO role in EPC function. Blood 2005; 105: 1846-7.
106. Ackah E, Yu J, Zoellner S, et al. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 2005; 115: 2119-27.
107. Kong D, Melo LG, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004; 109: 1769-75.
108. Gulati R, Jevremovic D, Witt TA, et al. Modulation of the vascular response to injury by autologous blood-derived outgrowth endothelial cells. Am J Physiol Heart Circ Physiol 2004; 287: H512-7.
109. Zhang LN, Wilson DW, da Cunha V, et al. Endothelial NO synthase deficiency promotes smooth muscle progenitor cells in association with upregulation of stromal cell-derived factor-1alpha in a mouse model of carotid artery ligation. Arterioscler Thromb Vasc Biol 2006; 26: 765-72.
110. Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol 2010; 55: 1553-65.
111. Duckers HJ, Soullie T, den Heijer P, et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). EuroIntervention 2007; 3: 350-8.
112. Nakazawa G, Granada JF, Alviar CL, et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 2010; 3: 68-75.
113. Low AF, Lee CH, Teo SG, et al. Effectiveness and safety of the genous endothelial progenitor cell-capture stent in acute STelevation myocardial infarction. Am J Cardiol 2011; 108: 202-5.
114. Lee YP, Tay E, Lee CH, et al. Endothelial progenitor cell capture stent implantation in patients with ST-segment elevation acute myocardial infarction: one year follow-up. EuroIntervention 2010; 5: 698-702.
115. Chong E, Poh KK, Liang S, et al. Two-year clinical registry follow-up of endothelial progenitor cell capture stent vs. sirolimuseluting bioabsorbable polymer-coated stent vs. bare metal stents in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction. J Interv Cardiol 2010; 23: 101-8.
116. Azzarelli S, Galassi AR, Grosso G, et al. Clinical and angiographic outcomes in elderly patients treated with endothelial progenitor cell capture coronary stents: results from a prospective single-center registry. J Invasive Cardiol 2010; 22: 594-8.
117. Beijk MA, Klomp M, Verouden NJ, et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J 2010; 31: 1055-64.
118. Bystron M, Cervinka P, Spacek R, et al. Randomized comparison of endothelial progenitor cells capture stent vs. cobalt-chromium stent for treatment of ST-elevation myocardial infarction. Sixmonth clinical, angiographic, and IVUS follow-up. Catheter Cardiovasc Interv 2010; 76: 627-31.
119. TM bio-engineered R stent in diabetic patients from the e-HEALING Registry. J Interv Cardiol 2011; 24: 285-94.
120. Kaul U, Bhatia V, Ghose T, Gupta R, Kachru R, Singh G. Angiographic follow-up of genous bioengineered stent in acute myocardial infarction (GENAMI)-a pilot study. Indian Heart J 2008; 60: 532-5.
121. Wendel HP, Avci-Adali M, Ziemer G. Endothelial progenitor cell capture stents--hype or hope? Int J Cardiol 2010; 145: 115-7.
122. Granada JF, Inami S, Aboodi MS, et al. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv 2010; 3: 257-66.
123. Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, Yoder MC. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 2005; 105: 2783-6.
124. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752-60.
125. Ingram DA, Krier TR, Mead LE, et al. Clonogenic endothelial progenitor cells are sensitive to oxidative stress. Stem Cells 2007; 25: 297-304.
126. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003; 108: 457-63.
127. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-7.
128. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-6.
129. Yokoyama T, Miyauchi K, Kurata T, Satoh H, Daida H. Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis 2004; 174: 253-9.
130. Fukuda D, Enomoto S, Shirakawa I, Nagai R, Sata M. Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment. Eur J Pharmacol 2009; 612: 87-92.
131. Indolfi C, Cioppa A, Stabile E, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000; 35: 214-21.
132. Hibbert B, Ma X, Pourdjabbar A, et al. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. PLoS One 2011; 6: e16413.
133. Hu Z, Zhang F, Yang Z, et al. Low-dose aspirin promotes endothelial progenitor cell migration and adhesion and prevents senescence. Cell Biol Int 2008; 32: 761-8.
134. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000; 342: 454-60.
135. Linke A, Schoene N, Gielen S, et al. Endothelial dysfunction in patients with chronic heart failure: systemic effects of lower-limb exercise training. J Am Coll Cardiol 2001; 37: 392-7.
136. Vona M, Codeluppi GM, Iannino T, Ferrari E, Bogousslavsky J, von Segesser LK. Effects of different types of exercise training followed by detraining on endothelium-dependent dilation in patients with recent myocardial infarction. Circulation 2009; 119: 1601-8.
137. Schlager O, Giurgea A, Schuhfried O, et al. Exercise training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in peripheral arterial disease: A randomized controlled trial. Atherosclerosis 2011; 217: 240-8.
138. Sonnenschein K, Horvath T, Mueller M, et al. Exercise training improves in vivo endothelial repair capacity of early endothelial progenitor cells in subjects with metabolic syndrome. Eur J Cardiovasc Prev Rehabil 2011 Feb 11. [Epub ahead of print].
139. Van Craenenbroeck EM, Hoymans VY, Beckers PJ, et al. Exercise training improves function of circulating angiogenic cells in patients with chronic heart failure. Basic Res Cardiol 2010; 105: 665-76.
140. Van Craenenbroeck EM, Beckers PJ, Possemiers NM, et al. Exercise acutely reverses dysfunction of circulating angiogenic cells in chronic heart failure. Eur Heart J 2010; 31: 1924-34.
141. Jenkins NT, Witkowski S, Spangenburg EE, Hagberg JM. Effects of acute and chronic endurance exercise on intracellular nitric oxide in putative endothelial progenitor cells: role of NAPDH oxidase. Am J Physiol Heart Circ Physiol 2009; 297: H1798-805.
142. Kostka T, Drai J, Berthouze SE, Lacour JR, Bonnefoy M. Physical activity, aerobic capacity and selected markers of oxidative stress and the anti-oxidant defence system in healthy active elderly men. Clin Physiol 2000; 20: 185-90.
143. Hambrecht R, Adams V, Erbs S, et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation 2003; 107: 3152-8.
144. Gielen S, Adams V, Mobius-Winkler S, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 861-8.
145. Ribeiro F, Alves AJ, Duarte JA, Oliveira J. Is exercise training an effective therapy targeting endothelial dysfunction and vascular wall inflammation? Int J Cardiol 2010; 141: 214-21.
146. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90: 844-53.
147. Mohler ER, 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation 2001; 103: 1522-8.
148. Matsumoto Y, Adams V, Walther C, et al. Reduced number and function of endothelial progenitor cells in patients with aortic valve stenosis: a novel concept for valvular endothelial cell repair. Eur Heart J 2009; 30: 346-55.
149. Matsumoto Y, Adams V, Jacob S, Mangner N, Schuler G, Linke A. Regular exercise training prevents aortic valve disease in lowdensity lipoprotein-receptor-deficient mice. Circulation 2010; 121: 759-67.
150. Fadini GP, Albiero M, Menegazzo L, et al. Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. Circ Res 2011; 108: 1112-21.
151. Matsumoto Y, Adams V, Jacob S, Mangner N, Schuler G, Linke A. Regular exercise training prevents aortic valve disease in lowdensity lipoprotein-receptor-deficient mice. Circulation 2010; 121: 759-67.
152. Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med 2006; 260: 192-210.
153. Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterraneanstyle diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 1440-6.
154. Yeung DK, Leung SW, Xu YC, Vanhoutte PM, Man RY. Puerarin, an isoflavonoid derived from Radix puerariae, potentiates endothelium-independent relaxation via the cyclic AMP pathway in porcine coronary artery. Eur J Pharmacol 2006; 552: 105-11.
155. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000; 35: 265-70.
156. Lefevre J, Michaud SE, Haddad P, et al. Moderate consumption of red wine (cabernet sauvignon) improves ischemia-induced neovascularization in ApoE-deficient mice: effect on endothelial progenitor cells and nitric oxide. FASEB J 2007; 21: 3845-52.
157. Fraga CG, Litterio MC, Prince PD, Calabro V, Piotrkowski B, Galleano M. Cocoa flavanols: effects on vascular nitric oxide and blood pressure. J Clin Biochem Nutr 2011; 48: 63-7.
158. Huang PH, Chen YH, Tsai HY, et al. Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability. Arterioscler Thromb Vasc Biol 2010; 30: 869-77.
159. Huang PH, Tsai HY, Wang CH, et al. Moderate intake of red wine improves ischemia-induced neovascularization in diabetic mice-roles of endothelial progenitor cells and nitric oxide. Atherosclerosis 2010; 212: 426-35.
160. Xia L, Wang XX, Hu XS, et al. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. Br J Pharmacol 2008; 155: 387-94.
161. Heiss C, Jahn S, Taylor M, et al. Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease. J Am Coll Cardiol 2010; 56: 218-24.
162. Suuronen EJ, Price J, Veinot JP, et al. Comparative effects of mesenchymal progenitor cells, endothelial progenitor cells, or their combination on myocardial infarct regeneration and cardiac function. J Thorac Cardiovasc Surg 2007; 134: 1249-58.
163. Tongers J, Roncalli JG, Losordo DW. Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. Microvasc Res 2010; 79: 200-6.
164. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106: 3009-17.
165. Wohrle J, Merkle N, Mailander V, et al. Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol 2010; 105: 804-12.
166. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199-209.
167. Tendera M, Wojakowski W, Ruzyllo W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009; 30: 1313-21.
168. Traverse JH, McKenna DH, Harvey K, et al. Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following STelevation myocardial infarction. Am Heart J 2010; 160: 428-34.
169. Schaefer A, Zwadlo C, Fuchs M, et al. Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial--an echocardiographic study. Eur J Echocardiogr 2010; 11: 165-71.
170. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009; 30: 2978-84.
171. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrowderived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367: 113-21.
172. Govaert JA, Swijnenburg RJ, Schrepfer S, et al. Poor functional recovery after transplantation of diabetic bone marrow stem cells in ischemic myocardium. J Heart Lung Transplant 2009; 28: 1158-65 e1.
173. Pijnappels DA, Schalij MJ, van Tuyn J, et al. Progressive increase in conduction velocity across human mesenchymal stem cells is mediated by enhanced electrical coupling. Cardiovasc Res 2006; 72: 282-91.
174. Badorff C, Brandes RP, Popp R, et al. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation 2003; 107: 1024-32.
175. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004; 428: 668-73.
176. Behfar A, Terzic A. Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny. Nat Clin Pract Cardiovasc Med 2006; 3 (Suppl 1): S78-82.
177. Fazel S, Cimini M, Chen L, et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006; 116: 1865-77.
178. Gruh I, Beilner J, Blomer U, et al. No evidence of transdifferentiation of human endothelial progenitor cells into cardiomyocytes after coculture with neonatal rat cardiomyocytes. Circulation 2006; 113: 1326-34.
179. Kawamoto A, Tkebuchava T, Yamaguchi J, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 2003; 107: 461-8.
180. Matsuura K, Wada H, Nagai T, et al. Cardiomyocytes fuse with surrounding non-cardiomyocytes and reenter the cell cycle. J Cell Biol 2004; 167: 351-63.
181. Mummery CL, Davis RP, Krieger JE. Challenges in using stem cells for cardiac repair. Sci Transl Med 2010; 2: 27ps17.
182. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664-8.
183. Schuster MD, Kocher AA, Seki T, et al. Myocardial neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. Am J Physiol Heart Circ Physiol 2004; 287: H525-32.
184. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 93-8.
185. Kim SK, Pak HN, Park JH, et al. Cardiac cell therapy with mesenchymal stem cell induces cardiac nerve sprouting, angiogenesis, and reduced connexin43-positive gap junctions, but concomitant electrical pacing increases connexin43-positive gap junctions in canine heart. Cardiol Young 2010; 20: 308-17.
186. Behfar A, Yamada S, Crespo-Diaz R, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010; 56: 721-34.
187. Schachinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690-9.
188. Kawamoto A, Iwasaki H, Kusano K, et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 2006; 114: 2163-9.
189. Iwasaki H, Kawamoto A, Ishikawa M, et al. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation 2006; 113: 1311-25.
190. Perin EC, Lopez J. Methods of stem cell delivery in cardiac diseases. Nat Clin Pract Cardiovasc Med 2006; 3 (Suppl 1): S110-3.
191. Hou D, Youssef EA, Brinton TJ, et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials Circulation 2005; 112 (9 Suppl): 150-6.
192. Graham JJ, Foltz WD, Vaags AK, et al. Long-term tracking of bone marrow progenitor cells following intracoronary injection post-myocardial infarction in swine using MRI. Am J Physiol Heart Circ Physiol 2010; 299: H125-33.
193. Godier-Furnemont AF, Martens TP, Koeckert MS, et al. Composite scaffold provides a cell delivery platform for cardiovascular repair. Proc Natl Acad Sci USA 2011; 108: 7974-9.
194. Kaminski A, Klopsch C, Mark P, et al. Autologous valve replacement-CD133+ stem cell-plus-fibrin composite-based sprayed cell seeding for intraoperative heart valve tissue engineering. Tissue Eng Part C Methods 2011; 17: 299-309.
195. Li TS, Cheng K, Lee ST, et al. Cardiospheres recapitulate a nichelike microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair. Stem Cells 2010; 28: 2088-98.
196. Zhang Y, Thorn S, DaSilva JN, et al. Collagen-based matrices improve the delivery of transplanted circulating progenitor cells: development and demonstration by ex vivo radionuclide cell labeling and in vivo tracking with positron-emission tomography. Circ Cardiovasc Imaging 2008; 1: 197-204.
197. Penn MS, Mangi AA. Genetic enhancement of stem cell engraftment, survival, and efficacy. Circ Res 2008; 102: 1471-82.
198. Haider H, Ashraf M. Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol 2008; 45: 554-66.
199. Tongers J, Losordo DW, Landmesser U. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J 2011; 32: 1197-206.
200. Sun L, Zhang T, Lan X, Du G. Effects of stem cell therapy on left ventricular remodeling after acute myocardial infarction: a metaanalysis. Clin Cardiol 2010; 33: 296-302.
201. Bai Y, Sun T, Ye P. Age, gender and diabetic status are associated with effects of bone marrow cell therapy on recovery of left ventricular function after acute myocardial infarction: a systematic review and meta-analysis. Ageing Res Rev 2010; 9: 418-23.
202. Siu CW, Liao SY, Liu Y, Lian Q, Tse HF. Stem cells for myocardial repair. Thromb Haemost 2010; 104: 6-12.
203. Roncalli J, Mouquet F, Piot C, et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J 2011; 32: 1748-57.
204. Ayach BB, Yoshimitsu M, Dawood F, et al. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci USA 2006; 103: 2304-9.
205. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 2011; 108: 792-6.
206. Henrich D, Seebach C, Wilhelm K, Marzi I. High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. J Surg Res 2007; 142: 13-9.
207. Deten A, Volz HC, Briest W, Zimmer HG. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002; 55: 329-40.
208. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and antideath strategies. J Mol Cell Cardiol 2001; 33: 907-21.
209. Cesari F, Sofi F, Caporale R, et al. Relationship between exercise capacity, endothelial progenitor cells and cytochemokines in patients undergoing cardiac rehabilitation. Thromb Haemost 2009; 101: 521-6.
210. Zhang Y, Ingram DA, Murphy MP, et al. Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2009; 296: H1675-82.
211. Li TS, Takahashi M, Suzuki R, et al. Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis. Ann Thorac Surg 2006; 81: 2217-25.
212. Hambrecht R, Gielen S, Linke A, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 2000; 283: 3095-101.
213. Villa A, Sanchez PL, Fernandez-Aviles F. Ventricular arrhythmias following intracoronary bone marrow stem cell transplantation. Europace 2007; 9: 1222-3.
214. Price MJ, Chou CC, Frantzen M, et al. Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol 2006; 111: 231-9.
215. Gepstein L. Electrophysiologic implications of myocardial stem cell therapies. Heart Rhythm 2008; 5(6 Suppl): S48-52.
216. de Boer TP, van der Heyden MA, Rook MB, et al. Pro-arrhythmogenic potential of immature cardiomyocytes is triggered by low coupling and cluster size. Cardiovasc Res 2006; 71: 704-14.
217. Itzhaki I, Schiller J, Beyar R, Satin J, Gepstein L. Calcium handling in embryonic stem cell-derived cardiac myocytes: of mice and men. Ann N Y Acad Sci. 2006 Oct; 1080: 207-15.
218. Schroder EA, Wei Y, Satin J. The developing cardiac myocyte: maturation of excitability and excitation-contraction coupling. Ann N Y Acad Sci 2006; 1080: 63-75.
219. Halbach M, Pfannkuche K, Pillekamp F, et al. Electrophysiological maturation and integration of murine fetal cardiomyocytes after transplantation. Circ Res 2007; 101: 484-92.
220. Zhang YM, Hartzell C, Narlow M, Dudley SC, Jr. Stem cellderived cardiomyocytes demonstrate arrhythmic potential. Circulation 2002; 106: 1294-9.
221. Bocchi L, Savi M, Graiani G, et al. Growth factor-induced mobilization of cardiac progenitor cells reduces the risk of arrhythmias, in a rat model of chronic myocardial infarction. PLoS One 2011; 6: e17750.
222. Katritsis DG, Sotiropoulou P, Giazitzoglou E, Karvouni E, Papamichail M. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace 2007; 9: 167-71.
223. Gardiwal A, Reissmann LM, Kotlarz D, et al. Arrhythmia susceptibility in mice after therapy with beta-catenin-transduced hematopoietic progenitor cells after myocardial ischemia/reperfusion. Cardiology 2009; 114: 199-207.
224. Leistner DM, Schmitt J, Palm S, et al. Intracoronary administration of bone marrow-derived mononuclear cells and arrhythmic events in patients with chronic heart failure. Eur Heart J 2011; 32: 485-91.
225. Ziebart T, Yoon CH, Trepels T, et al. Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res 2008; 103: 1327-34.
226. Forest VF, Tirouvanziam AM, Perigaud C, et al. Cell distribution after intracoronary bone marrow stem cell delivery in damaged and undamaged myocardium: implications for clinical trials. Stem Cell Res Ther 2010; 1: 4.
227. Tran N, Li Y, Maskali F, et al. Short-term heart retention and distribution of intramyocardial delivered mesenchymal cells within necrotic or intact myocardium. Cell Transplant 2006; 15: 351-8.
228. Goussetis E, Manginas A, Koutelou M, et al. Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution. Stem Cells 2006; 24: 2279-83.
229. Dow J, Simkhovich BZ, Kedes L, Kloner RA. Washout of transplanted cells from the heart: a potential new hurdle for cell transplantation therapy. Cardiovasc Res 2005; 67: 301-7.
230. Hayashi M, Li TS, Ito H, Mikamo A, Hamano K. Comparison of intramyocardial and intravenous routes of delivering bone marrow cells for the treatment of ischemic heart disease: an experimental study. Cell Transplant 2004; 13: 639-47.
231. Terrovitis JV, Smith RR, Marban E. Assessment and optimization of cell engraftment after transplantation into the heart. Circ Res 2010; 106: 479-94.
232. Gee AP, Richman S, Durett A, et al. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy 2010; 12: 684-91.
233. Tendera M, Wojakowski W. How to measure the effects of the intracoronary stem cell therapy? Eur J Echocardiogr 2010; 11: 438-9.
234. Frederick JR, Fitzpatrick JR 3rd, McCormick RC, et al. Stromal cell-derived factor-1alpha activation of tissue-engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovasculogenesis. Circulation 2010; 122(11 Suppl): S107-17.
235. Caspi O, Lesman A, Basevitch Y, et al. Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circ Res 2007; 100: 263-72.
236. Vunjak-Novakovic G, Tandon N, Godier A, et al. Challenges in cardiac tissue engineering. Tissue Eng Part B Rev 2010; 16: 169-87.
237. Kreutziger KL, Murry CE. Engineered human cardiac tissue. Pediatr Cardiol 2011; 32: 334-41.
238. Martinez EC, Kofidis T. Myocardial tissue engineering: the quest for the ideal myocardial substitute. Expert Rev Cardiovasc Ther 2009; 7: 921-8.
239. Stevens KR, Kreutziger KL, Dupras SK, et al. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci USA 2009; 106: 16568-73.
240. Zakharova L, Mastroeni D, Mutlu N, et al. Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc Res 2010; 87: 40-9.
241. Shimizu T, Sekine H, Yang J, et al. Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues. FASEB J 2006; 20: 708-10.
242. Van Laake LW, Van Donselaar EG, Monshouwer-Kloots J, et al. Extracellular matrix formation after transplantation of human embryonic stem cell-derived cardiomyocytes. Cell Mol Life Sci 2010; 67: 277-90.
243. Barash Y, Dvir T, Tandeitnik P, Ruvinov E, Guterman H, Cohen S. Electric field stimulation integrated into perfusion bioreactor for cardiac tissue engineering. Tissue Eng Part C Methods 2010; 16: 1417-26.
244. Mauritz C, Schwanke K, Reppel M, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008; 118: 507-17.
245. Burridge PW, Thompson S, Millrod MA, et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011; 6: e18293.
246. Pfannkuche K, Liang H, Hannes T, et al. Cardiac myocytes derived from murine reprogrammed fibroblasts: intact hormonal regulation, cardiac ion channel expression and development of contractility. Cell Physiol Biochem 2009; 24: 73-86.
247. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-7.
248. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471: 68-73.
249. Thum T, Hoeber S, Froese S, et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormonemediated increase of insulin-like growth-factor-1. Circ Res 2007; 100: 434-43.
250. Fazel S, Chen L, Weisel RD, et al. Cell transplantation preserves cardiac function after infarction by infarct stabilization: augmentation by stem cell factor. J Thorac Cardiovasc Surg 2005; 130: 1310.
251. Zemani F, Silvestre JS, Fauvel-Lafeve F, et al. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008; 28: 644-50.
252. Ma FX, Chen F, Ren Q, Han ZC. Lovastatin restores the function of endothelial progenitor cells damaged by oxLDL. Acta Pharmacol Sin 2009; 30: 545-52.
253. Jiang M, Wang B, Wang C, et al. Angiogenesis by transplantation of HIF-1 alpha modified EPCs into ischemic limbs. J Cell Biochem 2008; 103: 321-34.
254. Herrler T, Leicht SF, Huber S, et al. Prostaglandin E positively modulates endothelial progenitor cell homeostasis: an advanced treatment modality for autologous cell therapy. J Vasc Res 2009; 46: 333-46.
255. Chen TG, Chen JZ, Xie XD. Effects of aspirin on number, activity and inducible nitric oxide synthase of endothelial progenitor cells from peripheral blood. Acta Pharmacol Sin 2006; 27: 430-6.
256. Irhimeh MR, Fitton JH, Lowenthal RM. Fucoidan ingestion increases the expression of CXCR4 on human CD34+ cells. Exp Hematol 2007; 35: 989-94.
257. Zemani F, Benisvy D, Galy-Fauroux I, et al. Low-molecularweight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells. Biochem Pharmacol 2005; 70: 1167-75.
258. George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 2005; 68: 299-306.
259. Urbich C, Knau A, Fichtlscherer S, et al. FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. FASEB J 2005; 19: 974-6.
260. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003; 107: 1322-8.
261. Zheng H, Shen CJ, Qiu FY, Zhao YB, Fu GS. Stromal cell-derived factor 1alpha reduces senescence of endothelial progenitor subpopulation in lectin-binding and DiLDL-uptaking cell through telomerase activation and telomere elongation. J Cell Physiol 2010; 223: 757-63.
262. Imanishi T, Hano T, Nishio I. Estrogen reduces endothelial progenitor cell senescence through augmentation of telomerase activity. J Hypertens 2005; 23: 1699-706.
263. Hibbert B, Ma X, Pourdjabbar A, et al. Inhibition of endothelial progenitor cell glycogen synthase kinase-3beta results in attenuated neointima formation and enhanced re-endothelialization after arterial injury. Cardiovasc Res 2009; 83: 16-23.
264. Mias C, Trouche E, Seguelas MH, et al. Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells 2008; 26: 1749-57.
265. Sasaki K, Heeschen C, Aicher A, et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 2006; 103: 14537-41.
266. Ceradini DJ, Yao D, Grogan RH, et al. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 2008; 283: 10930-8.
267. Niessner A, Richter B, Penka M, et al. Endurance training reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque stabilization? Atherosclerosis 2006; 186: 160-5.
268. Steiner S, Niessner A, Ziegler S, et al. Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 2005; 181: 305-10.
269. Yang YJ, Qian HY, Huang J, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in postinfarct swine hearts. Eur Heart J 2008; 29: 1578-90.
270. Tang D, Lu J, Walterscheid JP, et al. Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res 2008; 49: 33-47.
271. Oikawa A, Siragusa M, Quaini F, et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 2010; 30: 498-508.
272. Shim W, Mehta A, Lim SY, et al. G-CSF for stem cell therapy in acute myocardial infarction: friend or foe? Cardiovasc Res 2011; 89: 20-30.
273. Bonig H, Chudziak D, Priestley G, Papayannopoulou T. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol 2009; 37: 402-15 e1.
274. Jujo K, Hamada H, Iwakura A, et al. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci USA 2010; 107: 11008-13.
275. Adams V, Lenk K, Linke A, et al. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc Biol 2004; 24: 684-90.
276. Cubbon RM, Murgatroyd SR, Ferguson C, et al. Human exerciseinduced circulating progenitor cell mobilization is nitric oxidedependent and is blunted in South Asian men. Arterioscler Thromb Vasc Biol 2010; 30: 878-84.
277. Rehman J, Li J, Parvathaneni L, et al. Exercise acutely increases circulating endothelial progenitor cells and monocyte/macrophage-derived angiogenic cells. J Am Coll Cardiol 2004; 43: 2314-8.
278. Sandri M, Adams V, Gielen S, et al. Effects of exercise and ischemia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes: results of 3 randomized studies. Circulation 2005; 111: 3391-9.
279. Hamed S, Alshiek J, Aharon A, Brenner B, Roguin A. Red wine consumption improves in vitro migration of endothelial progenitor cells in young, healthy individuals. Am J Clin Nutr 2010; 92: 161-9.
280. Urao N, Okigaki M, Yamada H, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Aktendothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 2006; 98: 1405-13.
281. Cacciatore F, Bruzzese G, Vitale DF, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients. Eur J Clin Pharmacol 2011; 67: 877-83.
282. Zaruba MM, Theiss HD, Vallaster M, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009; 4: 313-23.
283. Tian C, Bagley J, Forman D, Iacomini J. Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther 2006; 13: 652-8.
284. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005; 45: 1574-9.
285. Garg S, Duckers HJ, Serruys PW. Endothelial progenitor cell capture stents: will this technology find its niche in contemporary practice? Eur Heart J 2010; 31: 1032-5.
286. Hibbert B, Ma X, Pourdjabbar A, et al. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. PLoS One 2011; 6: e16413.
287. Erbs S, Beck EB, Linke A, et al. High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling--results from a randomized, double-blind, and placebo-controlled study. Int J Cardiol 2011; 146: 56-63.